Introduction
Benzodiazepines are among the most widely prescribed drugs, especially in anxiety-induced depression cases; stress, panic, and sleep disorders; muscle spasms; alcohol withdrawal; and seizures (1) . However, these substances are frequently present in emergency intoxication episodes and drugs-of-abuse testing, and they are often responsible for overdose in suicide attempts. Therefore, forensic toxicology laboratories must be able to screen, confirm, and quantify the main benzodiazepines and metabolites in biological samples.
Drug concentration can change after death due to postmortem redistribution and/or degradation. In fact, drug degradation can occur in the corpse before sample collection when there is a long period of time between death and matrix sampling; degradation due to substances' chemical decomposition or as a result of metabolic processes (e.g., bacteria enzyme activities) may occur (2) .
On the other hand, this degradation can also occur in vitro, during storage, particularly if there is a considerable time interval between sample collection and toxicological analysis (2) . Moreover, our forensic toxicology laboratories are obliged to keep biological samples for a certain period in order to allow reanalysis, if required in judicial cases, because of legal implications. Thus, it is important to study the instability of some toxicological substances stored at different conditions and in different biological samples, in order to try to explain the discrepancies found between the initial quantitative results and those obtained in a second demanded analysis.
There are many studies in the literature concerning substances stability, but these mainly report to drugs of abuse (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . Moreover, there are published studies with benzodiazepines (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) , but few have data related to the benzodiazepines investigated in the present work and were particularly performed in blood and plasma. Consequently, it is important to expand this stability study to other samples often used in forensic practice, for example, vitreous humor and bile. Two main advantages make those two alternative samples important for forensic analyses: vitreous humor can be very useful in forensic cases when blood is not available (18) ; bile samples are useful for detection of benzodiazepines and other drugs because of the significantly higher concentrations achieved in bile compared with blood (28, 29) . In fact, although bile is not commonly used for toxicological interpretation, it can be very useful, especially for forensic purposes. High levels found in bile can help determine that a toxic dose of a benzodiazepine was ingested. In the absence of blood, because bile accumulates some benzodiazepines, it may allow further information about possible exposure to these compounds. In fact, Vanbinst et al. (29) , recommended the analysis of bile, highlighting the importance of the data from this complementary fluid.
Because only limited data on benzodiazepine stability in vitreous humor have been reported (18) and no published data were found for bile samples, we included these two samples in our study.
The aim of the present study was the investigation of the stability of four different benzodiazepines (lorazepam, estazolam, chlordiazepoxide, and ketazolam) in different postmortem samples (blood, vitreous humor, and bile), under different storage times and temperatures. Additionally, the influence of sodium fluoride, often used preservative, on the stability of the benzodiazepines in blood and bile samples was also studied.
(1 mg/mL) and stored at -208C. Working solutions were also prepared in methanol.
All solvents were analytical or high-performance liquid chromatography (HPLC) grade and purchased from E. Merck (Darmstadt, Germany). Water was purified on a Milli-Q system obtained from Millipore (Molsheim, France). The mobile phase was filtered with a 0.20-mm Schleicher & Schuell filter and degassed in an ultrasonic bath for 15 min just before use.
Oasis w HLB (3 cc; 60 mg) solid-phase extraction (SPE) columns were obtained from Waters (ViaAthena, Portugal).
Sample collection and storage
Blank blood, vitreous humor, and bile samples were obtained from autopsies performed in the Forensic Pathology Department of the North Branch of the National Institute of Legal Medicine.
The pooled samples were fortified with the studied benzodiazepines in the concentration ranges usually detected in forensic intoxication cases (30 -36) (Table I) .
The fortified samples were separated into several aliquots, in polypropylene tubes, and stored at four different temperatures: room temperature (about 258C), 48C, -208C, and -808C. Blank pooled samples, representing a drug-free control, were also stored under the same conditions to verify the development of possible chromatographic peaks that could interfere with the quantitative determination of the analytes. Methanolic solutions of the benzodiazepines were also stored at identical temperatures, in order to differentiate between chemical and enzymatic degradation of the benzodiazepines.
Benzodiazepines degradation was also investigated, in fortified bile and blood samples containing sodium fluoride (NaF) (1%, w/v). The blood samples with NaF ( preserved blood samples) were not kept at -808C because of the lack of available sample.
Experimental protocol
Unpreserved blood samples, unpreserved and preserved bile samples, and methanolic solutions of the benzodiazepines were analyzed on the day of the sample preparation (day 0) and after 1, 2, 4, 8, 12, 16, 20 , and 24 weeks storage. Blood samples with NaF were only analyzed on day 0 and after 24 weeks storage. Vitreous humor samples were analyzed on day 0 and after 12 and 24 weeks storage.
We established the maximum percentage (100%) for concentrations detected in the first day (day 0) and the following quantifications were made taking into account the initial concentration, as the reference value.
Aliquots (five replicates) of the different studied samples were taken from each storage condition and were analyzed at different time intervals, according to the stability testing protocol described. Mean values of the five replicates were determined. A drug-free control sample was always analyzed in each analytical batch.
Sample preparation and SPE extraction
The internal standard, prazepam, was used by adding 80 mL of a 10 mg/mL solution (final concentration 0.8 mg/mL) to 1 mL of all the blood and vitreous humor samples examined, as well as 4 mL of water.
For bile, samples were diluted in a 1:99 proportion, by adding 4950 mL of water to 50 mL of fortified or blank bile samples. Prazepam was used by adding 160 mL of a 10 mg/mL solution (final concentration 1.6 mg/mL) to all the examined samples. Before extraction, the tubes were vortex mixed for 30 s, centrifuged for 20 min at 3900 rpm, and the supernatant decanted to another tube.
SPE was carried out on all the studied samples, using Oasis w HLB columns (3 cc; 60 mg). SPE columns were conditioned by sequentially adding 1 mL methanol and 1 mL water. The prepared samples were poured onto the conditioned columns and allowed to drain. Each column was then washed with 1 mL of a 5% methanol solution and dried under maximum vacuum for 5 min. The benzodiazepines were then eluted with 1 mL of methanol.
After filtrating with a 0.45-mm GHP filter, the solvent was evaporated to dryness, at 258C, under gentle nitrogen flow. Residues were redissolved with 100 mL of methanol, for blood and vitreous humor samples, or 200 mL of methanol, for bile samples, and vortex mixed to increase recovery from tube walls. Ten microliters of the final solution was then injected into the HPLC system.
Chromatographic conditions
HPLC-diode-array detection (DAD) analyses were conducted on a 2695 Alliance system liquid chromatograph (Waters) with a Waters 2996 DAD. Benzodiazepines separation was carried out using a Symmetry w C 18 column (3.9-mm i.d. Â 20 mm, 5 mm) from Waters, protected with a Symmetry w Guard Column (5 mm). A methanol/water mobile phase was used for compound separation, in the isocratic elution mode (60:40, v/v). The total run time was 35 min, at a flow rate of 0.8 mL/min. The separation was performed at 258C. The PDA detector was set to monitor the signal at 254 nm. In addition, the full ultraviolet spectrum between 210 and 400 nm of the detected peaks was stored in the data system. Instrument control, data acquisition, and processing were achieved by the use of Waters Empower software (Milford, MA).
Method validation
Validation studies were performed separately for each sample, vitreous humor, bile, and blood.
To evaluate peak purity and selectivity, 10 different blank samples (no analyte or internal standard added) were analyzed to check for peaks that might interfere with detection of the analyte or internal standard (IS). Negative samples (blank samples þ IS) were also analyzed in order to verify the absence of native analytes in the IS solution. The method showed that there was no interference from the sample matrix (absence of any interfering peak), and thus, the procedure proved to be selective and specific. Control and calibration samples were prepared by fortifying drug-free samples with standard solutions. One milliliter of drug-free blood and vitreous humor samples were first fortified with the studied benzodiazepines at concentrations ranging from 0.05 to 4.10 mg/L (Table II) for LOD and LOQ calculation. Moreover, for bile samples, 1 mL of drug-free sample was fortified with the studied benzodiazepines at concentrations ranging from 4.08 to 107 mg/L (Table II) .
The limits of detection (LOD) and quantitation (LOQ) were established using the residual standard deviation (S y/x ) and the slope of the linear regression (b), as LOD ¼ 3.3 S y/x /b and LOQ ¼ 10 S y/x /b (37, 38). After achieving the limits, concentration ranges were adjusted for the corresponding calibration/ quantitation validation studies (Table II) .
Extraction recovery was evaluated at three different concentration levels, comparing the representative peak areas of extracted drug-free samples fortified before extraction with the peak area of a methanolic solution of the benzodiazepines at the same concentrations.
Intraday coefficient of variation values were determined in blood and bile samples, on the same run (intraday). Three levels of concentration were selected for validation. The coefficient of variation was , 12% in all the tested samples. It was not possible to evaluate the intraday coefficient of variation in vitreous humor samples because of the limited blank sample available. All validation results are presented in Table II .
Statistical analysis
The results were statistically treated with the SPSS program (Statistical Package for Social Sciences). Differences between groups/conditions (storage temperature and time in the different matrices studied) were tested by performing the analysis of variance (ANOVA) followed by Duncan's post hoc test. Differences were considered significant at p , 0.05.
Results and Discussion
It was impossible to quantify, with the adopted methodology, the studied benzodiazepines in all of the samples after 12 weeks of storage at room temperature because of the blood decomposition and consequent interferant production.
Lorazepam
We concluded that after six months, lorazepam remained stable in all samples stored at -208C and -808C (Table III) , although some studies found a 15% decrease in lorazepam concentration in postmortem blood samples stored for six months at -208C (23). However, lorazepam appeared to be unstable at positive temperatures. In fact, after six months at 48C, lorazepam had a considerable decrease, very similar when comparing unpreserved bile, vitreous humor, and preserved blood samples (22-24%), a decline also observed by other authors (23) who analyzed postmortem blood samples (stored for the same period of time at 48C). Nevertheless, this decrease was less significant in preserved bile samples (10%), but was augmented in unpreserved blood samples (37%).
After 12 weeks stored at room temperature, lorazepam concentrations had a similar decrease in unpreserved bile and vitreous humor samples (58% and 59%, respectively). The decrease was lower in preserved bile samples (45%), but it was especially significant in unpreserved blood samples (78%). At the end of the study, it was impossible to measure any lorazepam in preserved blood samples because of the presence of an interfering substance, but the other samples stored at room temperature (unpreserved and preserved bile samples and vitreous humor) showed a 46 -63% reduction in lorazepam concentration. Moreover, lorazepam degradation was also observed in methanolic solutions, suggesting a possible chemical degradation of this benzodiazepine (23% and 54% loss in methanolic solutions, kept six months at 48C and room temperature, respectively). However, the addition of sodium fluoride to blood and bile samples seemed to prevent lorazepam degradation and loss by preventing growth of microorganisms due to putrefaction that may be present in postmortem samples, enhancing degradation.
Estazolam
Estazolam appears to be the most stable of the studied benzodiazepines. Effectively, its concentration remained stable during the six months storage at negative temperatures and at 48C, in all the analyzed samples (Table IV) . In fact, Pe´pin et al. (23) also considered estazolam to be a stable benzodiazepine, even though they reported a 20% decrease in estazolam concentration in postmortem blood samples stored two and six months at -208C and at 48C and a 25% decrease in estazolam concentrations stored two and six months at room temperature (23) . However, chromatographic interference was detected in bile samples after 7 days storage, which made the study of estazolam stability in both unpreserved and preserved bile samples impossible. After 8 weeks, estazolam chromatographic peaks detected in unpreserved blood samples stored at room temperature were not spectrally homogeneous and thus, this benzodiazepine was not quantified after the mentioned period.
In our study, estazolam concentrations in blood samples stored at room temperature strongly increased (37%, after 8 weeks). The increase observed in estazolam concentrations in unpreserved blood samples stored at room temperature could be attributed to the water content decrease in blood samples because the blank blood samples stored at the same conditions did not show any peaks in the retention time of estazolam that could interfere with the quantitative determination of this benzodiazepine. This water loss process due to an evaporation phenomenon was also described in other stability studies (39) (40) (41) . In fact, after 2 weeks storage, estazolam concentration increased 36%, and this increase remained almost stable until 8 weeks of storage (37%). Once again, methanolic solutions kept at room temperature also presented an increase in this benzodiazepine concentration.
We may assume that the presence of a triazole ring on estazolam molecule may be responsible for the observed estazolam stability, as some authors clarify that this group is very resistant to hydrolysis (42) .
Ketazolam
This study revealed that ketazolam is the most unstable benzodiazepine. In all the samples stored at positive temperatures (48C and 258C), a dramatic decrease in ketazolam occurred and thus, it was no longer possible to detect this benzodiazepine after 1 -2 weeks at room temperature and after 8 -12 weeks at 48C (Table V) . Ketazolam was totally degraded (100%) in methanolic solutions stored at 48C and at room temperature. In fact, it was no longer possible to detect ketazolam after 1 and 8 weeks stored at room temperature and at 48C, respectively, suggesting a chemical degradation of this benzodiazepine. Nevertheless, this drug showed a relative stability at -208C and at -808C during the 6 months of storage, with only a 4 -7% reduction in vitreous humor, 10 -11% in unpreserved bile, and 13% in unpreserved blood. In preserved blood and preserved bile samples, kept at negative temperatures, there was no statistical difference in ketazolam concentrations.
In this study it was also possible to characterize and quantify compounds that could have been formed due to ketazolam degradation. In fact, when analyzing the samples for ketazolam, we detected diazepam in all the samples stored at room temperature and at 48C. In blood, after 6 months storage, diazepam levels were very similar to the added ketazolam concentration (0.162 mg/L of diazepam versus 0.20 mg/L of the fortified ketazolam). Interestingly, the preservation of blood and bile samples with NaF 1% had no protective effect on the degradation of ketazolam.
Thus, when interpreting toxicological results related to a possible ketazolam exposure, it is important to consider that the presence of diazepam in biological samples can be due to ketazolam biotransformation (in vivo), but also due to its postmortem decomposition (in the corpse or in vitro). In fact, if samples are kept at positive temperatures, in vitro degradation into diazepam is, indeed, very quickly, as observed in the present study. However, as explained, it is important to note that in vivo, ketazolam can be rapidly metabolized, by N-demethylation, to desmethylketazolam and nordiazepam, but some other metabolites can also be detected, such as diazepam, oxazepam, temazepam, and other unidentified metabolites (32) .
Standard solutions of ketazolam should be kept at negative temperatures, or prepared daily, because we observed a loss of 40% in its concentration and simultaneously detected diazepam after just one week when methanolic solutions were kept at 48C.
Chlordiazepoxide
This study demonstrated that methanolic solutions kept at 48C and at room temperature had chlordiazepoxide degradation (59% and 76% decreasing, respectively, after six weeks). In fact, it was possible to detect three chlordiazepoxide degradation products in these methanolic solutions, one of the products being demoxepam, which is produced by the methylamino group lost (43) . Moreover, demoxepam was detected in solutions stored at room temperature for one week and after two weeks in solutions stored at 48C, and its concentrations increased over the six months. We also detected two other different chromatographic peaks, one probably more polar than chlordiazepoxide and another less polar, but it was not possible to identify them. Indeed, chemical degradation of chlordiazepoxide has been already reported by some authors (42, 43) . However, methanolic solutions kept at -208C and -808C confirmed that chlordiazepoxide concentration remained stable over a 6-month period.
When we analyzed the biological matrices, we observed that chlordiazepoxide degradation was also marked in samples stored at positive temperatures (Table VI) .
Although some studies had reported a 50% decrease in chlordiazepoxide concentration in samples stored for 2 months at -208C (23), in our study, chlordiazepoxide concentration remained almost stable in all biological samples stored at -208C and -808C.
As also reported by other authors, we were able to demonstrate chlordiazepoxide instability in samples stored at 48C and at room temperature (20, 23, 25, 27) . Additionally, in unpreserved blood samples stored at positive temperatures there was a rapid decline in chlordiazepoxide concentrations. In fact, after 4 weeks storage at 48C, there was a 47% decrease in its concentration, and after 8 weeks, it was no longer possible to detect this benzodiazepine (LOD ¼ 0.202 mg/L). Our results are consistent with other studies, where a 70% chlordiazepoxide loss after 2 months of storage at 48C was observed (23) , as well as a 45-50% decrease in blood samples stored at 48C over 2 weeks (25) . Some other authors concluded that chlordiazepoxide only remains stable for 5 to 12 days in fortified liver samples stored at 48C (27) . As expected (25) , sodium fluoride seemed to prevent chlordiazepoxide degradation; in our study, in preserved blood samples, after six months it was still possible to recover 40% of the initial chlordiazepoxide concentration. However, we achieved better stability results in the alternative matrices. Indeed, unpreserved and preserved bile samples stored at 48C for 6 months had a 48% and 29% decrease in chlordiazepoxide concentration, respectively, and vitreous humor samples stored at 48C for 6 months had a 61% decrease in chlordiazepoxide concentration (Table VI) .
Chlordiazepoxide instability was higher in samples stored at room temperature, where a total degradation of chlordiazepoxide was observed in all the samples stored over six months, except for preserved bile samples, where it was still possible to recover 30% of the initial chlordiazepoxide concentration. In unpreserved blood samples stored at room temperature, it was not possible to detect chlordiazepoxide after just the first week. This total degradation of chlordiazepoxide had also been reported in other stability studies (20, 23, 25) .
While we were studying chlordiazepoxide stability, we detected other substances that formed due to its degradation. In fact, demoxepam was detected in all the samples stored at room temperature and at 48C, and nordiazepam was present in all the samples stored at room temperature and in both preserved unpreserved blood and vitreous humor samples stored at 48C. A substance with a mass-to-charge ratio comparable to the desoxychlordiazepoxide mass-to-charge ratio (284) was present in unpreserved blood and bile samples stored at room temperature and in unpreserved blood samples stored at 48C. However, it was not possible to confirm this peak because of the absence of the corresponding chemical standard. As reported in the literature, the formation of chlordiazepoxide breakdown products in biological samples stored at 48C and at room temperature may occur, with the consequent detection of demoxepam and nordiazepam in blood samples fortified with chlordiazepoxide (25) . Moreover, desoxychlordiazepoxide and nordiazepam production can also be produced in liver samples fortified with chlordiazepoxide (27) .
We could also observe that in unpreserved blood samples, demoxepam concentration started to decrease with the simultaneous increase of nordiazepam concentration, suggesting demoxepam degradation into nordiazepam. However, nordiazepam concentrations increased even after the total degradation of demoxepam, suggesting a possible conversion of desoxychlordiazepoxide into nordiazepam. The data now obtained suggest that chlordiazepoxide degradation with consequent demoxepam production may occur by chemical breakdown, since it has also occurred in methanolic stored solutions, as mentioned previously. However, the presence of NaF in preserved blood samples made chlordiazepoxide degradation to demoxepam much slower, suggesting that decomposition may also occur due to microorganisms' activity, as also described by other authors (25) . In the biological samples, probably due to the activity of some enzymes synthesized by microorganisms during the putrefactive process, the oxygen atom lost from the N-oxide group of chlordiazepoxide molecule yielding desoxychlordiazepoxide because this compound was not detected in preserved samples, as described by some authors (27) . Both, desoxychlordiazepoxide and demoxepam, are transformed in nordiazepam (Figure 1) . It was also possible to notice that sodium fluoride addition resulted in a slower demoxepam to nordiazepam degradation, suggesting, once again, the microorganism's action.
In bile samples, even though no NaF was added, chlordiazepoxide was more stable than in blood samples, and this could be explained by the fact that this alternative sample has no proper microorganism's environment for the species development and consequent substance degradation. In these samples, desoxychlordiazepoxide and nordiazepam production only occurred when samples were kept at room temperature. Moreover, vitreous humor samples also presented a higher stability when compared to blood, and this could be due to the upper resistance to microbial activities shown by this matrix due to its anatomic isolation, which is an advantage, especially in postmortem cases where tissue decomposition may have occurred.
When interpreting toxicological results, it is important to remember that demoxepam and nordiazepam are, in fact, chlordiazepoxide metabolites, but they can also be postmortem breakdown products of this benzodiazepine.
Conclusions
Benzodiazepines concentration can change after death due to degradation before sample collection or during specimens' storage. Effectively, biological samples for toxicological analysis frequently remain at room temperature for some hours during transport, reception and registration, at 48C during some days until drug screening and analysis confirmation, and at negative temperatures for several months or years for legal purposes and possible reanalysis. Some factors can influence drugs stability, such as storage time and temperature, the preservatives addition (such as NaF), and the type of the collected sample. In fact, we concluded that generally, benzodiazepines degradation increased with temperature and storage time growth. We observed no difference between samples stored at -808C and at -208C. In fact, the benzodiazepines studied showed a relative good stability during the six months storage at negative temperatures.
NaF (1% w/v) addition to blood and bile samples could be advantageous, especially in cases where degradation by microorganisms may occur. Bile and vitreous humor seem to be more suitable samples than blood samples when in vitro degradation of benzodiazepines occurs.
Quantitative results from long-term stored samples should be interpreted cautiously. Thus, in order to assure a correct interpretation of the toxicological results it is important to know the stability of the drugs at several conditions of storage and in different matrices.
